- Rafael Holdings, Inc. (RFL) announced that an independent Data Monitoring Committee recommended the **continuation of its Trappsol® Cyclo Phase 3 clinical trial** for Niemann-Pick Disease Type C1 (NPC1) following an interim analysis in **June 2025**.  **[1713863_0001213900-25-097965_ea026090801ex99-1_rafael.htm:1]** **[1713863_0001213900-25-097965_ea026090801ex99-1_rafael.htm:2]**  The **final analysis is targeted for the first half of 2026**, with potential regulatory submissions to the FDA and EMA by the **end of 2026**.  **[1713863_0001213900-25-097965_ea026090801ex99-1_rafael.htm:2]** **[1713863_0001213900-25-097965_ea026090801ex99-1_rafael.htm:6]** 
- As of **April 30, 2025**, the company reported a **cash balance of approximately $62.8 million** and stated it has sufficient capital to fund through multiple value-creating milestones.  **[1713863_0001213900-25-097965_ea026090801ex99-1_rafael.htm:6]** 
- The global market for Niemann-Pick Disease is projected to exceed **$920 million by 2033**.  **[1713863_0001213900-25-097965_ea026090801ex99-1_rafael.htm:6]** 
- Rafael Holdings received **FDA approval in December 2024** for an all-in-one Endoscopic Carpal Tunnel Release system.  **[1713863_0001213900-25-097965_ea026090801ex99-1_rafael.htm:6]**

Rafael Holdings (RFL)